نتایج جستجو برای: anaplastic lymphoma kinase

تعداد نتایج: 333698  

2016
Carolina Valeria Mahuad María de los Ángeles Vicente Repáraz Marta E. Zerga María Florencia Aizpurua Claudia Casali Gonzalo Garate

The prognosis of the primary refractory anaplastic lymphoma kinase (ALK+) anaplastic T large cell lymphoma is ominous. The identification of molecular targets with potential to drive oncogenesis remains a cornerstone for the designing of new selective cancer therapies. Crizotinib is a selective ATP-competitive inhibitor for ALK, approved for its use in lung cancer with rearrangements on ALK gen...

Journal: :Molecular cancer therapeutics 2007
Sergey V Krysov Tania F Rowley Aymen Al-Shamkhani

CD30, a non-death domain-containing member of the tumor necrosis factor receptor superfamily, triggers apoptosis in anaplastic large cell lymphoma cells. The CD30 signaling pathways that lead to the induction of apoptosis are poorly defined. Here, we show that the induction of apoptosis by CD30 requires concurrent inhibition of p38 mitogen-activated protein kinase, which itself is activated by ...

2017
Michael T Werner Qian Zhang Mariusz A Wasik

Anaplastic large cell lymphoma expressing anaplastic lymphoma kinase (ALK+ ALCL) is a distinct subtype of non-Hodgkin lymphoma. In this review, we discuss the historical findings that led to its classification as a unique disease, despite its varied clinical presentation and histology. We discuss the molecular mechanisms underlying ALK+ ALCL pathology and the questions that remain in the field....

2015
Liting Guo Haijun Zhang Weiwei Shao Baoan Chen

Crizotinib, the first clinically designed and synthesized as a tyrosine kinase inhibitor targeting mesenchymal-epithelial transition factor, indicating marked anticancer activity in patients with advanced, anaplastic lymphoma kinase-positive non-small-cell lung cancer, was approved by the US Food and Drug Administration in 2011. In this review, we focus on the efficacy of crizotinib compared wi...

2016
Shalin Kothari Najam Ud-Din Michele Lisi Thomas Coyle

BACKGROUND In vitro studies confirmed cytoreductive anti-tumor activity of crizotinib in experimental models of anaplastic large cell lymphoma in 2007. One case series and a few case reports describe the use of crizotinib in relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Even though data are limited regarding the dose of crizotinib in renal insufficie...

Journal: :Haematologica 2013
Ilske Oschlies Jasmin Lisfeld Laurence Lamant Atsuko Nakazawa Emanuele S G d'Amore Ulrika Hansson Konnie Hebeda Ingrid Simonitsch-Klupp Jadwiga Maldyk Leonhard Müllauer Marianne Tinguely Markus Stücker Marie-Cecile Ledeley Reiner Siebert Alfred Reiter Laurence Brugières Wolfram Klapper Wilhelm Woessmann

Anaplastic large cell lymphomas are peripheral T-cell lymphomas that are characterized by a proliferation of large anaplastic blasts expressing CD30. In children, systemic anaplastic large cell lymphomas often present at advanced clinical stage and harbor translocations involving the anaplastic lymphoma kinase (ALK) gene leading to the expression of chimeric anaplastic lymphoma kinase (ALK)-fus...

2016
Chen Tian Yizhuo Zhang

INTRODUCTION Most primary stomach lymphomas are now recognized to originate from B-cell. Primary gastric anaplastic lymphoma kinase (ALK)-negative anaplastic large-cell lymphoma (ALCL) as shown in this case is very rare. CASE REPORT A 59-year-old man presented with a 1-month history of epigastric pain. Computed tomography showed a tumor in the stomach with perigastric lymphadenopathy. Biopsy ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید